Home/Filings/4/0001415889-21-002268
4//SEC Filing

Watkin Jared 4

Accession 0001415889-21-002268

CIK 0000001800other

Filed

May 3, 8:00 PM ET

Accepted

May 4, 7:07 PM ET

Size

15.4 KB

Accession

0001415889-21-002268

Insider Transaction Report

Form 4
Period: 2021-04-30
Watkin Jared
Senior Vice President
Transactions
  • Exercise/Conversion

    Option (right to buy)

    2021-04-3017,0430 total
    Exercise: $44.40From: 2018-02-17Exp: 2027-02-16Common Shares (17,043 underlying)
  • Sale

    Common shares without par value

    2021-04-30$119.89/sh85,043$10,195,62759,783 total
  • Sale

    Common shares without par value

    2021-04-30$120.02/sh9,533$1,144,11359,783 total
  • Exercise/Conversion

    Common shares without par value

    2021-04-30$59.94/sh+68,000$4,075,920144,826 total
  • Exercise/Conversion

    Option (right to buy

    2021-04-3068,00033,987 total
    Exercise: $59.94From: 2019-02-16Exp: 2028-02-15Common Shares (68,000 underlying)
  • Exercise/Conversion

    Common shares without par value

    2021-04-30$44.40/sh+17,043$756,70976,826 total
Holdings
  • Common shares without par value

    (indirect: By Trust)
    602
Footnotes (4)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.0103 to $120.08, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.38 to $120.13, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F3]Balance in the Abbott Laboratories Stock Retirement Trust as of April 30, 2021.
  • [F4]Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

Issuer

ABBOTT LABORATORIES

CIK 0000001800

Entity typeother

Related Parties

1
  • filerCIK 0001645118

Filing Metadata

Form type
4
Filed
May 3, 8:00 PM ET
Accepted
May 4, 7:07 PM ET
Size
15.4 KB